Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (NCT05215340)
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)
🩺 Plain-English Summary (8th-Grade Level)
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Who can join: Review the eligibility criteria below.
Location: Ironwood Cancer and Research Center — Chandler, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (234 Sites)
Showing the first 25 of 234 sites.
- Ironwood Cancer and Research Center — Chandler, Arizona
- UCLA HemOnc - Clinical Research Unit — Los Angeles, California
- Ridley-Tree Cancer Center — Santa Barbara, California
- PIH Health Whittier Hospital — Whittier, California
- The Oncology Institute of Hope and Innovation — Whittier, California
- Uch-Mhs D/B/A Memorial Health System — Colorado Springs, Colorado
- Johns Hopkins University — Baltimore, Maryland
- American Oncology Partners of Maryland — Bethesda, Maryland
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana Farber Cancer Institute - Foxborough — Foxborough, Massachusetts
- DFCI - South Shore Hospital — South Weymouth, Massachusetts
- Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
- Astera Cancer Care — East Brunswick, New Jersey
- Regional Cancer Care Associates LLC — Freehold, New Jersey
- Cooperman Barnabas Medical Center — New Brunswick, New Jersey
- The Valley Hospital — Paramus, New Jersey
- Montefiore Medical Center — The Bronx, New York
- Arizona Oncology NAHOA — Irving, Texas
- Cancer Care Center of Brevard — Irving, Texas
- Illinois Cancer Specialists — Irving, Texas
- Maryland Oncology Hematology — Irving, Texas
- Southern Cancer Center — Irving, Texas
- Texas Oncology - Northeast Texas — Irving, Texas
- Texas Oncology Gulf Coast — Irving, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Non Small Cell Lung Cancer
- Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation — Cerritos, California
- Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) — St Louis, Missouri
- Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) — Daphne, Alabama
- Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer — Gilbert, Arizona
- MOv19-BBz CAR T Cells in FRa+ Cancers — Philadelphia, Pennsylvania
Explore by condition: All Metastatic Non Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.